Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi MTLH Out-licenses Innovative Cancer Drug to Shanghai Pharma

publication date: Mar 25, 2010
Wuxi MTLH Biotechnology Co., a company founded in December 2007, has sold the China rights for its lead molecule, an anti-cancer drug, to Shanghai The First Biochemical Pharmaceutical Co. Ltd., a subsidiary of Shanghai Pharmaceutical Group. MTLH-001 is a peptide PDGFR antagonist in pre-clinical development. SBPC will co-develop the product with MTLH according to FDA standards, helping MTLH to launch the drug globally. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital